Does Rallies show 13F holders for HCAT?

Yes. Rallies tracks hedge fund and 13F ownership data for HCAT, including fund names, share counts, latest tracked quarter, and position changes when available.

Is HCAT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for HCAT. It does not provide personalized investment advice.

HCAT (Health Catalyst, Inc Common Stock) Stock Analysis - Hedge Fund Holdings

Health Catalyst, Inc Common Stock (HCAT) is a publicly traded Healthcare sector company. As of May 21, 2026, HCAT trades at $1.29 with a market cap of $93.85M and a P/E ratio of -0.34. HCAT moved +2.36% today. Year to date, HCAT is -43.67%; over the trailing twelve months it is -67.26%. Its 52-week range spans $0.96 to $9.24. Analyst consensus is neutral with an average price target of $2.11. Rallies surfaces HCAT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns HCAT stock?

Hedge funds tracked by Rallies that own HCAT include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Health Catalyst, Inc Common Stock.

HCAT Key Metrics

Key financial metrics for HCAT
Metric	Value
Price	$1.29
Market Cap	$93.85M
P/E Ratio	-0.34
EPS	$-3.74
Dividend Yield	0.00%
52-Week High	$9.24
52-Week Low	$0.96
Volume	0
Avg Volume	0
Revenue (TTM)	$302.48M
Net Income	$-265.26M
Gross Margin	0.00%

Top Hedge Funds Holding HCAT

Exoduspoint Capital holds 97.12K shares of HCAT, changed +542.56% as of Mar 31, 2025.

Latest HCAT News

Health Catalyst Q1 Revenue Drops 11% to $70.8M as Adjusted EBITDA Jumps 46% — May 11, 2026
Health Catalyst Elevates Ben Albert to CEO, Board Downsized to Five Directors — Feb 18, 2026
Health Catalyst Drops 20.4% in Four Weeks as EPS Estimates Surge 128% — Feb 16, 2026
Health Catalyst Slumps 6.8% to $1.85 After Strong Payrolls Temper AI Optimism — Feb 12, 2026

Recent HCAT Insider Trades

Landry Benjamin sold 27.43K (~$72.33K) on Dec 5, 2025.
Larson-Green Julie sold 48.00K (~$128.35K) on Dec 4, 2025.
Landry Benjamin sold 6.17K (~$20.70K) on Sep 5, 2025.

HCAT Analyst Consensus

9 analysts cover HCAT: 0 strong buy, 2 buy, 7 hold, 0 sell, 0 strong sell. Consensus rating is neutral. Average price target: $2.11.

Common questions about HCAT

Who owns HCAT stock?: Hedge funds tracked by Rallies that own HCAT include Exoduspoint Capital. The latest tracked quarter is Mar 31, 2025. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Health Catalyst, Inc Common Stock.
Does Rallies show 13F holders for HCAT?: Yes. Rallies tracks hedge fund and 13F ownership data for HCAT, including fund names, share counts, latest tracked quarter, and position changes when available.
Is HCAT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for HCAT. It does not provide personalized investment advice.